Mirza-Schreiber, N. ; Zech, M. ; Wilson, R. ; Brunet, T. ; Wagner, M. ; Jech, R.* ; Boesch, S.* ; Škorvánek, M.* ; Necpál, J.* ; Weise, D.* ; Weber, S. ; Mollenhauer, B.* ; Trenkwalder, C.* ; Maier, E.M.* ; Borggraefe, I.* ; Vill, K.* ; Hackenberg, A.* ; Pilshofer, V.* ; Kotzaeridou, U.* ; Schwaibold, E.M.C.* ; Hoefele, J.* ; Waldenberger, M. ; Gieger, C. ; Peters, A. ; Meitinger, T.* ; Schormair, B.* ; Winkelmann, J. ; Oexle, K.
Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onset.
Brain, DOI: 10.1093/brain/awab360 (2021)
Dystonia is a prevalent, heterogeneous movement disorder characterized by involuntarily abnormal postures. Biomarkers of dystonia are notoriously lacking. Here, a biomarker is reported for histone lysine methyltransferase (KMT2B)-deficient dystonia, a leading subtype among the individually rare monogenic dystonias. It was derived by applying a support vector machine to an episignature of 113 DNA CpG sites which, in blood cells, showed significant epigenome-wide association with KMT2B deficiency and at least 1x log-fold change of methylation. This classifier was accurate both when tested on the general population and on samples with various other deficiencies of the epigenetic machinery, thus allowing for definitive evaluation of variants of uncertain significance and identifying patients who may profit from deep brain stimulation, a highly successful treatment in KMT2B-deficient dystonia. Methylation was increased in KMT2B deficiency at all 113 CpG sites. The coefficients of variation of the normalized methylation levels at these sites also perfectly classified the samples with KMT2B-deficient dystonia. Moreover, the mean of the normalized methylation levels correlated well with the age at onset of dystonia (p = 0.003) - being lower in samples with late or incomplete penetrance-thus serving as a predictor of disease onset and severity. Similarly, it may also function in monitoring the recently envisioned treatment of KMT2B deficiency by inhibition of DNA methylation.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Kmt2b ; Age At Onset ; Dystonia ; Episignature ; Mode Of Inheritance; Kmt2b; Classification; Episignatures; Diagnosis
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2021
Prepublished im Jahr
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
0006-8950
e-ISSN
1460-2156
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band:
Heft:
Seiten:
Artikelnummer:
Supplement:
Reihe
Verlag
Oxford University Press
Verlagsort
Great Clarendon St, Oxford Ox2 6dp, England
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30205 - Bioengineering and Digital Health
30202 - Environmental Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-503200-001
G-504091-001
G-503292-001
G-504091-004
G-504000-010
Förderungen
Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ
European Reference Network for Rare Neurological Diseases
Technische Universitat Munchen, Munich, Germany
Helmholtz Zentrum Munchen, Munich, Germany
Charles University, Prague, Czech Republic
Czech Ministry of Education
European Joint Programme on Rare Diseases (EJP RD COFUND-EJP)
Slovak Grant and Development Agency
Operational Programme Integrated Infrastructure - ERDF
Helmholtz Zentrum MunchenGerman Research Center for Environmental Health - German Federal Ministry of Education and Research (BMBF)
State of Bavaria
German Research Foundation
Copyright
Erfassungsdatum
2021-11-23